Justin Klee (L) and Josh Cohen (Amylyx)
In a twist, Amylyx's ALS drug will get a second crack at adcomm endorsement after FDA decides to reconvene experts
After a close negative vote earlier this year, Amylyx Pharmaceuticals will get another attempt to persuade FDA advisors that its experimental ALS drug is effective …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
